Form 8-K - Current report:
SEC Accession No. 0001641172-25-021595
Filing Date
2025-07-30
Accepted
2025-07-30 17:29:20
Documents
13
Period of Report
2025-07-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 48942
  Complete submission text file 0001641172-25-021595.txt   262506

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE asbp-20250724.xsd EX-101.SCH 3800
3 XBRL DEFINITION FILE asbp-20250724_def.xml EX-101.DEF 26654
4 XBRL LABEL FILE asbp-20250724_lab.xml EX-101.LAB 36742
5 XBRL PRESENTATION FILE asbp-20250724_pre.xml EX-101.PRE 25278
15 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5857
Mailing Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928
Business Address 23150 FASHION DRIVE, SUITE 232 ESTERO FL 33928 561-704-8527
Aspire Biopharma Holdings, Inc. (Filer) CIK: 0001847345 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)